15(S)-HETE Ethanolamide – 100 µg

Brand:
Cayman
CAS:
161744-53-2
Storage:
-20
UN-No:
De Minimis - 1170 / 3

Arachidonoyl ethanolamide (AEA; Item No. 90050) was the first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB1 and CB2) as THC.{1134,2713} Since that time, a number of related endocannabinoids have been isolated, most notably 2-arachidonoyl glycerol (Item No. 62160).{2713} Lipoxygenases, especially rabbit reticulocyte and soybean 15-lipoxygenases, actively convert endocannabinoids to their 15(S)-hydroperoxy and hydroxy metabolites.{11412} 15(S)-HETE ethanolamide is less potent than AEA at the CB1 receptor (Ki of 600 versus 90 nM). 15(S)-HETE ethanolamide also inhibits fatty acid amide hydrolase.{11365}  

 

Available on backorder

SKU: 10169 - 100 µg Category:

Description

Less potent than AEA (Item No. 90050) at the CB1 receptor (Ki = 600 versus 90 nM); inhibits FAAH


Formal name: 15(S)-hydroxy-N-(2-hydroxyethyl)-5Z,8Z,11Z,13E-eicosatetraenamide

Synonyms:  15(S)-HAEA

Molecular weight: 363.5

CAS: 161744-53-2

Purity: ≥98%

Formulation: A solution in ethanol


Product Type|Biochemicals|Lipids|Fatty Amides||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Small Molecule Inhibitors|Fatty Acid Metabolism||Research Area|Lipid Biochemistry|Endocannabinoid/Endocannabinoid-like||Research Area|Lipid Biochemistry|Lipoxygenase Pathways||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors||Research Area|Neuroscience|Cannabinoid Research|Endocannabinoids